Recce Pharmaceuticals (ASX: RCE) — Company Overview, News & Financial Data
Recce Pharmaceuticals is a biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and viral pathogens.
Recce Pharmaceuticals
Recce Pharmaceuticals is a biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and viral pathogens. The company's lead synthetic polymer compounds are engineered to maintain potency without inducing cellular resistance, offering potential treatments for life-threatening microbial infections. Recce Pharmaceuticals advances multiple clinical development programs, including intravenous formulations for systemic conditions such as sepsis and urosepsis, and topical applications for acute bacterial skin infections, burn wounds, and diabetic foot ulcers. The company conducts clinical trials across Australia and international jurisdictions while operating specialized manufacturing capabilities to supply synthetic candidates for ongoing regulatory trials.
Snapshot
Operations
Products and/or services of Recce Pharmaceuticals
- Intravenous Anti-Infective Therapy: Formulation administered via intravenous infusion targeting serious systemic infections, including sepsis and urosepsis, currently undergoing Phase 2 clinical trials across clinical sites in Australia to evaluate safety, efficacy, and dosage profiles.
- Topical Burn Wound Anti-Infective: Gel-based synthetic polymer formulation developed for topical application to treat acute bacterial skin and skin structure infections, including burn wound infections, undergoing clinical evaluation in Australian hospital centers.
- Diabetic Foot Infection Anti-Infective: Topical synthetic compound designed for treating complicated diabetic foot ulcers and associated bacterial infections, evaluated in registrational clinical trials in Indonesia and Australia to address multidrug-resistant pathogens.
- Urinary Tract Infection Therapeutics: Systemic anti-infective program evaluating intravenous delivery for complicated urinary tract infections, targeting acute and recurrent uropathogenic bacterial strains resistant to conventional antibiotic treatments in Phase 2 clinical trials.
- Anti-Viral Synthetic Candidates: Pre-clinical and early-stage development program evaluating synthetic polymer compounds against viral pathogens, focusing on broad-spectrum anti-viral activity and universal mechanisms of action against rapidly mutating viral pathogen strains.
- Automated Manufacturing Operations: In-house clinical manufacturing facility located in Macquarie Park, Sydney, Australia, supporting automated pilot-scale batch production, quality testing, and supply of synthetic anti-infective formulations for ongoing clinical trials.
Recce Pharmaceuticals executive team
- John K. A. PrendergastExecutive Chairman of the Board
- James Hamilton-Bray GrahamCEO, MD & Executive Director
- Michele Keryn DiliziaChief Scientific Officer & Executive Director
- Justin WardHead of Chemistry, Principal Quality Chemist & Executive Director
- Arthur KollarasPrincipal Engineer & Head of Manufacturing
- Alan W. DuntonChief Medical Advisor & Non Executive Director
- Justin ReynoldsChief Financial Officer
- Daniel AstudilloHead of Marketing
- Maggie NiewidokCompany Secretary
Latest news about Recce Pharmaceuticals
Recce Pharmaceuticals secures Australian commercialisation deal
AustraliaRecce Pharmaceuticals submits clinical trial data for R327G
AustraliaRecce Pharmaceuticals highlights US$66.9B biodefence strategy
AustraliaRecce Pharmaceuticals receives new patent expiring 2041
AustraliaRecce Pharmaceuticals raises $4M via placement, eyes $4M more
AustraliaRecce Pharmaceuticals advances diabetec foot infection trial
Australia
Recent announcements
What Recce Pharmaceuticals (RCE) has told the market, newest first.
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - RCE
- HREC Approval Accelerates Global Phase 3 DFI StrategyPrice sensitive
Key financials
Reported results for Recce Pharmaceuticals, in AUD.
- Market cap
- 100.9M
- Revenue (TTM)
- 9.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- -158.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -23.2M | -15M | |
| 7.5M | -22.9M | -21.4M | |
| 5M | -22.1M | -17.7M | |
| 4.4M | -17.3M | -13.1M |